- Previous Close
22.20 - Open
22.00 - Bid 22.60 x --
- Ask 22.80 x --
- Day's Range
22.00 - 22.00 - 52 Week Range
20.60 - 32.40 - Volume
223 - Avg. Volume
3 - Market Cap (intraday)
535.027M - Beta (5Y Monthly) 1.16
- PE Ratio (TTM)
-- - EPS (TTM)
-1.20 - Earnings Date Mar 4, 2025 - Mar 10, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products. Its products comprise PediLoc, PediPlates, cannulated screws, PediFlex nail, PediNail, PediLoc Tibia, ACL Reconstruction System, Locking Cannulated Blade, Locking Proximal Femur, Spica Tables, RESPONSE Spine, BandLoc, Pediguard, Pediatric Nailing Platform | Femur, Devise Rail, Orthex, The Fassier-Duval Telescopic Intramedullary System, SLIMTM Nail, The GAP Nail, The Free Gliding SCFE Screw System, GIROTM Growth Modulation System, PNP Tibia System, ApiFix Mid-C System, and Mitchell Ponseti. The company serves pediatric orthopedic market, as well as pediatric orthopedic surgeons and caregivers. OrthoPediatrics Corp. was founded in 2006 and is headquartered in Warsaw, Indiana.
www.orthopediatrics.comRecent News: 2X7.F
View MorePerformance Overview: 2X7.F
Trailing total returns as of 1/3/2025, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 2X7.F
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 2X7.F
View MoreValuation Measures
Market Cap
535.03M
Enterprise Value
531.75M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.78
Price/Book (mrq)
1.50
Enterprise Value/Revenue
2.90
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-15.00%
Return on Assets (ttm)
-3.94%
Return on Equity (ttm)
-7.63%
Revenue (ttm)
189.67M
Net Income Avi to Common (ttm)
-28.44M
Diluted EPS (ttm)
-1.20
Balance Sheet and Cash Flow
Total Cash (mrq)
76.06M
Total Debt/Equity (mrq)
21.36%
Levered Free Cash Flow (ttm)
-50.25M